Table 2. Rank Probability of Best Outcomes by Treatment for ARR.

	Rank 1	Rank 2	Rank 3	Rank 4	Rank 5	Rank 6	Rank 7	SUCRA
Placebo	0.00	0.00	0.00	0.00	0.01	0.56	99.43	0.00
IFN beta-1a 30 μg QW	0.34	1.60	4.56	13.91	30.76	48.81	0.02	0.30
IFN beta-1b 250 μg EOD	6.58	15.21	23.32	26.67	20.16	8.05	0.01	0.56
IFN b-1a 22 μg TIW	6.75	9.05	12.76	18.69	27.95	24.57	0.23	0.46
IFN beta-1a 44 μg TIW	17.99	27.00	25.65	20.84	7.58	0.94	0.00	0.71
GA 20 mg OD	26.09	36.28	24.65	9.90	2.44	0.64	0.00	0.79
PEG IFN beta-1a 125 μg every 2 weeks	42.25	10.86	9.06	10.00	11.09	16.43	0.31	0.69

Abbreviations: ARR, annualized relapse rate; CDP3M, 3-month confirmed disability progression; CDP6M, 6-month confirmed disability progression; EOD, every other day; GA, glatiramer acetate; IFN, interferon; μg, microgram; OD, once daily; PEG, pegylated; QW, once a week; SUCRA, surface under the cumulative ranking curve; TIW, 3 times a week